- CA$8.44bn
- CA$15.28bn
- $5.10bn
Brief: Bausch + Lomb And Bausch Health Announce Appointment Of Thomas J. Appio As Interim Bausch + Lomb CEO, Expect To Raise Full-Year 2026 Guidance
Bausch + Lomb CEO Saunders steps down, Chairman Appio appointed interim chief
Brief: US FDA sent warning letter to Bausch & Lomb on September 4
Brief: Bausch + Lomb Announces European CE Mark Approval Of Seelyra™ Femtosecond Laser
Brief: Bausch + Lomb Advancing Two First-In-Class Eye Health Therapies Based On Trial Results
Brief: Bausch + Lomb Q2 Adjusted EPS USD 0.15 Vs. IBES Estimate USD 0.15
Refile: BUZZ-Bausch + Lomb stops glaucoma eye drop development, US-listed shares drop
Bausch to stop glaucoma eye drop development after trial miss
Brief: Bausch + Lomb To Discontinue BL1107 Eye Drop Development For Glaucoma
Cooper Companies beats quarterly estimates on strong contact lenses demand (updated)
Cooper Companies beats quarterly profit estimate on strong contact lenses demand
Brief: Bausch + Lomb Launches Blink® Triple Care Preservative Free Lubricant Eye Drops In The United States
Bausch + Lomb Q1 revenue rises 9%, beats estimates; lifts 2026 outlook
Brief: Bausch + Lomb Study Reviews B Vitamins' Impact on Macular Degeneration
US FDA declines to approve Aldeyra's eye disorder drug, shares slump (updated)
US FDA declines to approve Aldeyra's drug for eye disorder
FedEx customers sue company for tariff refunds after US Supreme Court ruling
Toymaker Hasbro joins wave of companies suing U.S. government over IEEPA tariff payments
L'Oreal, Dyson, Bausch + Lomb become the latest to sue for Trump tariff refunds (updated)